Lecavalier, Luc http://orcid.org/0000-0002-1162-659X
Pan, Xueliang
Smith, Tristram
Handen, Benjamin L.
Arnold, L. Eugene
Silverman, Laura
Tumuluru, Rameshwari V.
Hollway, Jill
Aman, Michael G.
Funding for this research was provided by:
National Institute of Mental Health (R01MH079082-01A2)
Article History
First Online: 11 October 2017
Compliance with Ethical Standards
:
: Dr. Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for AMO Pharma, CogState, Inc.; Confluence Pharmaceutica; CogState Clinical Trials, Ltd.; Coronado Biosciences; Forest Research; Hoffman-La Roche; Johnson & Johnson, Lumos Pharma, MedAvante, Inc.; Novartis; Ovid Therapeutics, ProPhase LLC; and Supernus Pharmaceuticals. Dr. Handen has received research support from Lilly, Roche, Curemark, Autism Speaks, NIMH, and NIA. Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, YoungLiving, NIH and Autism Speaks. He has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint. He has been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and received travel support from Noven. Dr. Hollway has received research funding from Forest Research Institute, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Young Living, F. Hoffman-La Roche AG, and Autism Speaks. Drs. Lecavalier, Pan, Smith, Tumuluru, and Silverman, have no conflicts of interest to report.
: Informed consent was obtained from all individual participants who were included in this article.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.